Sales & Marketing

KYV-101 designed as a CD19 CAR T-cell therapy.

Site aims to advance regenerative medicines on a global scale.

Cosentyx is the first intravenous formulation interleukin-17A antagonist to focus on disease.

Developed by Bio-Thera Solutions, treatment is indicated for patients with three different types of arthritis.

Acquisition includes company’s inflammatory disease medicines.

Addition strengthens neuroscience pipeline, company says.

Lofaso discusses strategies that biotech companies can take once its time to make the big push.

Transaction made with intent to develop new drugs, company says.

Company expects treatment to be available across the country.

Separate entity allows company to concentrate on status as focused medicines company.

Collaboration to focus on ulcerative colitis and Crohn’s disease.

Acquired company focused on radioligand therapies for the treatment of cancer.

Currently in Phase III of clinical trials, Sanofi is expected to commercialize vaccine candidate.

Pombiliti + Opfolda indicated for adults who are not improving on current enzyme therapy.

Eye drop treatment indicated for pharmacologically induced mydriasis.

Deal comes amid first successful partnership.

Company expects to yield a significant number of new medicine launches from the acquisition.

Collaboration to focus on Alzheimer’s and Huntington's disease.

Ginko will be eligible for up to $331 million in milestone payments.

Teams expected to collaborate on development and commercialization of multiple targets.

Transaction expected to close at the end of this year for $19 a share.

Shares expected to be offered on Six Swiss Exchange.

Collaboration based on Valo’s large human dataset and computation powered by artificial intelligence.

Deal comes amid previous exclusive marketing agreement.

Company brings aboard former Pfizer exec as life sciences COO in effort to help further improve patient outcomes.